COVID-19, Infectious Disease
Conditions
Brief summary
The AGMT\_COVID-19 Registry is designed as multicenter observational cohort of patients, that are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing to participate. Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF.
Detailed description
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified at the end of 2019 in Wuhan, the capital of Hubei province in central China, and has since spread globally. There are currently no authorised vaccines or treatments in the EU (European Union) to prevent or treat novel coronavirus disease (COVID-19) specifically or any other coronaviruses. The AGMT\_COVID-19 Registry is designed as multicenter observational cohort of patients, that are tested positive for SARS-CoV-2. Data will be collected from all sites in Austria willing to participate. Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician.
Interventions
None listed
Sponsors
Arbeitsgemeinschaft medikamentoese Tumortherapie
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>=18 years * Positive test for SARS-CoV-2
Exclusion criteria
* Due to the non-interventional design of the registry there are no specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Documentation of natural course and the therapeutic landscape of patients with COVID-19. | 2 years | Due to the non-interventional nature of the AGMT\_COVID-19 registry, only routine data, which has already been recorded in the patient's medical chart, is transferred to the eCRF. Treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations, and response assessments shall be exclusively based on the risk/benefit estimation of the treating physician. |
Countries
Austria
Contacts
Primary ContactDaniela Wolkersdorfer, Dr.
Backup ContactStephanie Esmaeilzadeh-Leithner, MSc.
Outcome results
None listed